中毒症治療法の世界市場:アルコール中毒治療薬、たばこ中毒治療薬、薬物中毒治療薬

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Alcohol addiction therapeutics – Market size and forecast 2018-2023

Tobacco addiction therapeutics – Market size and forecast 2018-2023

Drug addiction therapeutics – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 10: MARKET TRENDS

Increasing R&D of novel drugs

Emergence of free state-run addiction treatment programs and facilities

Consolidation of rehabilitation centers

PART 11: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 12: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Alkermes Plc

Amneal Pharmaceuticals Inc.

Indivior Plc

Johnson & Johnson Services Inc.

Mylan NV

Novartis AG

Novo Nordisk AS

Opiant Pharmaceuticals Inc.

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

PART 13: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Alcohol addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Alcohol addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 22: Tobacco addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Tobacco addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Drug addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Drug addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by type

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Alkermes Plc – Vendor overview

Exhibit 51: Alkermes Plc – Business segments

Exhibit 52: Alkermes Plc – Organizational developments

Exhibit 53: Alkermes Plc – Geographic focus

Exhibit 54: Alkermes Plc – Key offerings

Exhibit 55: Alkermes Plc – Key customers

Exhibit 56: Amneal Pharmaceuticals Inc. – Vendor overview

Exhibit 57: Amneal Pharmaceuticals Inc. – Business segments

Exhibit 58: Amneal Pharmaceuticals Inc. – Organizational developments

Exhibit 59: Amneal Pharmaceuticals Inc. – Segment focus

Exhibit 60: Amneal Pharmaceuticals Inc. – Key offerings

Exhibit 61: Amneal Pharmaceuticals Inc. – Key customers

Exhibit 62: Indivior Plc – Vendor overview

Exhibit 63: Indivior Plc – Business segments

Exhibit 64: Indivior Plc – Organizational developments

Exhibit 65: Indivior Plc – Geographic focus

Exhibit 66: Indivior Plc – Key offerings

Exhibit 67: Indivior Plc – Key customers

Exhibit 68: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 69: Johnson & Johnson Services, Inc. – Business segments

Exhibit 70: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 71: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 72: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 73: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 74: Johnson & Johnson Services, Inc. – Key customers

Exhibit 75: Mylan NV – Vendor overview

Exhibit 76: Mylan NV – Product segments

Exhibit 77: Mylan NV – Organizational developments

Exhibit 78: Mylan NV – Geographic focus

Exhibit 79: Mylan NV – Segment focus

Exhibit 80: Mylan NV – Key offerings

Exhibit 81: Mylan NV – Key customers

Exhibit 82: Novartis AG – Vendor overview

Exhibit 83: Novartis AG – Business segments

Exhibit 84: Novartis AG – Organizational developments

Exhibit 85: Novartis AG – Geographic focus

Exhibit 86: Novartis AG – Segment focus

Exhibit 87: Novartis AG – Key offerings

Exhibit 88: Novartis AG – Key customers

Exhibit 89: Novo Nordisk AS – Vendor overview

Exhibit 90: Novo Nordisk AS – Business segments

Exhibit 91: Novo Nordisk AS – Organizational developments

Exhibit 92: Novo Nordisk AS – Geographic focus

Exhibit 93: Novo Nordisk AS – Segment focus

Exhibit 94: Novo Nordisk AS – Key offerings

Exhibit 95: Novo Nordisk AS – Key customers

Exhibit 96: Opiant Pharmaceuticals Inc. – Vendor overview

Exhibit 97: Opiant Pharmaceuticals Inc. – Business segments

Exhibit 98: Opiant Pharmaceuticals Inc. – Organizational developments

Exhibit 99: Opiant Pharmaceuticals Inc. – Key offerings

Exhibit 100: Opiant Pharmaceuticals Inc. – Key customers

Exhibit 101: Pfizer Inc. – Vendor overview

Exhibit 102: Pfizer Inc. – Business segments

Exhibit 103: Pfizer Inc. – Organizational developments

Exhibit 104: Pfizer Inc. – Geographic focus

Exhibit 105: Pfizer Inc. – Segment focus

Exhibit 106: Pfizer Inc. – Key offerings

Exhibit 107: Pfizer Inc. – Key customers

Exhibit 108: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 113: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 114: Validation techniques employed for market sizing

Exhibit 115: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様